Scarica l'app Stockscreener
7.10
1.21%
0.085
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$7.015
Aprire:
$7.03
Volume 24 ore:
888.71K
Relative Volume:
0.35
Capitalizzazione di mercato:
$324.59M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-8.5542
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
-10.80%
1M Prestazione:
+8.90%
6M Prestazione:
-52.67%
1 anno Prestazione:
+55.02%
Intervallo 1D:
$6.92
$7.2992
Intervallo di 1 settimana:
$6.9007
$7.9999
Portata 52W:
$3.98
$23.40
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
10865 ROAD TO THE CURE, SAN DIEGO, CA
Confronta CAPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
7.10 | 352.02M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Iniziato | Alliance Global Partners | Buy |
| 2025-06-26 | Iniziato | B. Riley Securities | Buy |
| 2025-05-20 | Iniziato | Roth Capital | Buy |
| 2024-10-21 | Iniziato | Piper Sandler | Overweight |
| 2024-05-17 | Iniziato | Oppenheimer | Outperform |
| 2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
| 2018-01-26 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-15 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
| 2016-07-06 | Ripresa | H.C. Wainwright | Buy |
| 2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
CAPR Investors Have the Opportunity to Lead the Capricor Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - FinancialContent
Best data tools to analyze Capricor Therapeutics Inc. stockBear Alert & Verified Swing Trading Watchlists - Newser
Leading vs lagging indicators on Capricor Therapeutics Inc. performance - Newser
Published on: 2025-08-20 02:01:26 - Newser
Technical analysis overview for Capricor Therapeutics Inc. stock2025 Volatility Report & Real-Time Market Trend Scan - Newser
Applying big data sentiment scoring on Capricor Therapeutics Inc.Quarterly Trade Review & Accurate Trade Setup Notifications - Newser
Published on: 2025-08-19 23:32:36 - Newser
How to build a custom watchlist for Capricor Therapeutics Inc.2025 Volatility Report & Weekly Top Gainers Trade List - Newser
Is Capricor Therapeutics Inc. forming a reversal patternMarket Growth Review & Low Risk Entry Point Tips - Newser
Real time alert setup for Capricor Therapeutics Inc. performanceJuly 2025 Trends & Consistent Profit Trade Alerts - Newser
CAPR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - Morningstar
Published on: 2025-08-19 05:33:56 - Newser
What the charts say about Capricor Therapeutics Inc. todayJuly 2025 Recap & Accurate Buy Signal Notifications - Newser
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
Capricor Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. September 15, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
Capricor Therapeutics, Inc. Securities Fraud Class Action - GlobeNewswire
Capricor Initiates First-in-Human Trial of StealthX™ Vaccine Under NIAID’s Project NextGen - Quiver Quantitative
Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine - GlobeNewswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) should contact The Gross Law Firm about pending Class ActionCAPR - PR Newswire
SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces A - GlobeNewswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
What makes Capricor Therapeutics Inc. stock price move sharplyGap Up & Low Risk High Win Rate Stock Picks - Newser
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Capricor Therapeutics, Inc. – CAPR - FinancialContent
Price action breakdown for Capricor Therapeutics Inc.Long Setup & Detailed Earnings Play Alerts - Newser
Momentum divergence signals in Capricor Therapeutics Inc. chartQuarterly Profit Review & AI Powered Market Entry Ideas - Newser
Live market analysis of Capricor Therapeutics Inc.Rate Hike & Technical Confirmation Trade Alerts - Newser
When is the best time to exit Capricor Therapeutics Inc.July 2025 Big Picture & Smart Allocation Stock Tips - Newser
Bragar Eagel & Squire, P.C. Urges Investors in XPLR - GlobeNewswire
Bragar Eagel & Squire, P.C. Urges Investors in XPLR Infrastructure, Centene, Biohaven, or Capricor to Inquire About Their Rights in Class Action Lawsuits - Morningstar
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc.CAPR - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors to Secure ... - Eagle-Tribune
Custom watchlist performance reports with Capricor Therapeutics Inc.Long Setup & Safe Capital Growth Stock Tips - Newser
Published on: 2025-08-16 02:13:07 - Newser
Published on: 2025-08-15 23:36:43 - beatles.ru
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - WV News
Faruqi & Faruqi Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025CAPR - The Malaysian Reserve
Capricor Therapeutics shares rise 2.19% premarket after the announcement of the Second Quarter 2025 Conference Call. - AInvest
CAPR FY2025 EPS Estimate Lowered by Cantor Fitzgerald - Defense World
HC Wainwright Issues Pessimistic Estimate for CAPR Earnings - Defense World
Roth Capital Has Bearish Estimate for CAPR Q3 Earnings - Defense World
Class Action Lawsuit Filed Against Capricor Therapeutics, Inc. (CAPR)Recover LossesContact Levi & Korsinsky Before September 15, 2025 - ACCESS Newswire
Transcript : Capricor Therapeutics, Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class ... - Bluefield Daily Telegraph
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Capricor Therapeutics, Inc.(CAPR) Shareholders - Morningstar
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Capricor Therapeutics Inc Azioni (CAPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bergmann Anthony | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Option Exercise |
1.39 |
2,500 |
3,475 |
8,223 |
| Litvack Frank | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
25,000 |
34,750 |
132,382 |
| DUNBAR GEORGE W JR | Director |
Mar 03 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
11,306 |
| COLLIER EARL M JR | Director |
Feb 27 '25 |
Option Exercise |
1.39 |
750 |
1,042 |
57,606 |
| Krasney Karen | EVP, GENERAL COUNSEL |
Dec 13 '24 |
Option Exercise |
1.39 |
8,000 |
11,120 |
28,047 |
| Litvack Frank | Director |
Dec 03 '24 |
Option Exercise |
1.10 |
20,391 |
22,430 |
46,278 |
| Nippon Shinyaku Co Ltd | 10% Owner |
Sep 20 '24 |
Buy |
5.36 |
2,798,507 |
14,999,998 |
7,090,351 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):